421 related articles for article (PubMed ID: 16304147)
1. Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis.
Clemons KV; Espiritu M; Parmar R; Stevens DA
Antimicrob Agents Chemother; 2005 Dec; 49(12):4867-75. PubMed ID: 16304147
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic and toxicologic studies in a murine model of invasive pulmonary aspergillosis.
Clemons KV; Schwartz JA; Stevens DA
Med Mycol; 2011 Nov; 49(8):834-47. PubMed ID: 21539507
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Abelcet and caspofungin, alone or in combination, against CNS aspergillosis in a murine model.
Imai J; Singh G; Fernandez B; Clemons KV; Stevens DA
J Antimicrob Chemother; 2005 Jul; 56(1):166-71. PubMed ID: 15917284
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Abelcet alone, or in combination therapy, against experimental central nervous system aspergillosis.
Clemons KV; Parmar R; Martinez M; Stevens DA
J Antimicrob Chemother; 2006 Aug; 58(2):466-9. PubMed ID: 16760192
[TBL] [Abstract][Full Text] [Related]
5. Differences in efficacy and cytokine profiles following echinocandin or liposomal amphotericin B monotherapy or combination therapy for murine pulmonary or systemic Aspergillus flavus infections.
Olson JA; Schwartz J; Hahka D; George A; Proffitt RT; Adler-Moore JP
Antimicrob Agents Chemother; 2012 Jan; 56(1):218-30. PubMed ID: 21968353
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of micafungin alone or in combination against experimental pulmonary aspergillosis.
Clemons KV; Stevens DA
Med Mycol; 2006 Feb; 44(1):69-73. PubMed ID: 16805095
[TBL] [Abstract][Full Text] [Related]
7. Experimental central nervous system aspergillosis therapy: efficacy, drug levels and localization, immunohistopathology, and toxicity.
Clemons KV; Schwartz JA; Stevens DA
Antimicrob Agents Chemother; 2012 Aug; 56(8):4439-49. PubMed ID: 22687510
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis.
Kirkpatrick WR; Perea S; Coco BJ; Patterson TF
Antimicrob Agents Chemother; 2002 Aug; 46(8):2564-8. PubMed ID: 12121933
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin.
Olson JA; Adler-Moore JP; Smith PJ; Proffitt RT
Antimicrob Agents Chemother; 2005 Dec; 49(12):4895-902. PubMed ID: 16304150
[TBL] [Abstract][Full Text] [Related]
10. [Efficacies and clinical roles of new antifungal agents].
Tokimatsu I; Kadota J
Nihon Ishinkin Gakkai Zasshi; 2006; 47(3):155-9. PubMed ID: 16940948
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of voriconazole plus amphotericin B or micafungin in a guinea-pig model of invasive pulmonary aspergillosis.
Chandrasekar PH; Cutright JL; Manavathu EK
Clin Microbiol Infect; 2004 Oct; 10(10):925-8. PubMed ID: 15373889
[TBL] [Abstract][Full Text] [Related]
12. Assessing the antifungal activity, pharmacokinetics, and tissue distribution of amphotericin B following the administration of Abelcet and AmBisome in combination with caspofungin to rats infected with Aspergillus fumigatus.
Wasan KM; Sivak O; Rosland M; Risovic V; Bartlett K
J Pharm Sci; 2007 Jul; 96(7):1737-47. PubMed ID: 17080414
[TBL] [Abstract][Full Text] [Related]
13. Economic evaluation of targeted treatments of invasive aspergillosis in adult haematopoietic stem cell transplant recipients in the Netherlands: a modelling approach.
Ament AJ; Hübben MW; Verweij PE; de Groot R; Warris A; Donnelly JP; van 't Wout J; Severens JL
J Antimicrob Chemother; 2007 Aug; 60(2):385-93. PubMed ID: 17561501
[TBL] [Abstract][Full Text] [Related]
14. Successful medical treatment of cutaneous aspergillosis in a premature infant using liposomal amphotericin B, voriconazole and micafungin.
Santos RP; Sánchez PJ; Mejias A; Benjamin DK; Walsh TJ; Patel S; Jafri HS
Pediatr Infect Dis J; 2007 Apr; 26(4):364-6. PubMed ID: 17414408
[TBL] [Abstract][Full Text] [Related]
15. Use of newer antifungal therapies in clinical practice: what do the data tell us?
Perfect JR
Oncology (Williston Park); 2004 Nov; 18(13 Suppl 7):15-23. PubMed ID: 15651178
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of amphotericin B or amphotericin B-intralipid in combination with caspofungin against experimental aspergillosis.
Sionov E; Mendlovic S; Segal E
J Infect; 2006 Aug; 53(2):131-9. PubMed ID: 16360214
[TBL] [Abstract][Full Text] [Related]
17. Assessing the antifungal activity and toxicity profile of amphotericin B lipid complex (ABLC; Abelcet) in combination with caspofungin in experimental systemic aspergillosis.
Sivak O; Bartlett K; Risovic V; Choo E; Marra F; Batty DS; Wasan KM
J Pharm Sci; 2004 Jun; 93(6):1382-9. PubMed ID: 15124198
[TBL] [Abstract][Full Text] [Related]
18. Caspofungin: antifungal activity in vitro, pharmacokinetics, and effects on fungal load and animal survival in neutropenic rats with invasive pulmonary aspergillosis.
van Vianen W; de Marie S; ten Kate MT; Mathot RA; Bakker-Woudenberg IA
J Antimicrob Chemother; 2006 Apr; 57(4):732-40. PubMed ID: 16464895
[TBL] [Abstract][Full Text] [Related]
19. A case of Aspergillus mediastinitis after heart transplantation successfully treated with liposomal amphotericin B, caspofungin and voriconazole.
Forestier E; Remy V; Lesens O; Martinot M; Hansman Y; Eisenmann B; Christmann D
Eur J Clin Microbiol Infect Dis; 2005 May; 24(5):347-9. PubMed ID: 15889298
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis.
MacCallum DM; Whyte JA; Odds FC
Antimicrob Agents Chemother; 2005 Sep; 49(9):3697-701. PubMed ID: 16127042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
